Drug combination for fighting skin cancer approved for NHS use Medicines regulator NICE moves at record speed to approve nivolumab for use with ipilimumab in melanoma patients
A combination of two immunotherapy drugs for advanced skin cancer has been approved for general use in the NHS, raising hopes that the deadly disease will be stalled and perhaps eradicated in many more patients.
The National Institute for Health and Care Excellence (NICE) has approved nivolumab for use with ipilimumab within a couple of months of the combination getting a licence. Patients with advanced melanoma in England and Wales will be the first in Europe to get it, says NICE. Continue reading... The Guardian
See also:
A combination of two immunotherapy drugs for advanced skin cancer has been approved for general use in the NHS, raising hopes that the deadly disease will be stalled and perhaps eradicated in many more patients.
The National Institute for Health and Care Excellence (NICE) has approved nivolumab for use with ipilimumab within a couple of months of the combination getting a licence. Patients with advanced melanoma in England and Wales will be the first in Europe to get it, says NICE. Continue reading... The Guardian
See also:
No comments:
Post a Comment